Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
118.51
Oct 23 • 3:59 PM ET Dollar change+2.35 Percentage change(2.02%)
Aftermarket Close
118.51
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
5.39B
Enterprise Value
6.34B
Income
96.29M
Sales
1.35B
Book/sh
18.41
Cash/sh
4.91
Employees
3009
IPO
May 10, 1991
P/E
57.80
Forward P/E
20.37
PEG
1.99
P/S
3.99
P/B
6.44
P/C
24.14
P/FCF
18.51
EV/EBITDA
17.70
EV/Sales
4.69
Quick Ratio
1.91
Current Ratio
3.08
Debt/Eq
1.40
LT Debt/Eq
1.40
Option/Short
Yes / Yes
EPS (ttm)
2.05
EPS next Y
5.82
EPS next Q
1.29
EPS this Y
7.12%
EPS next Y
9.50%
EPS next 5Y
10.25%
EPS past 3/5Y
-2.90% 5.81%
Sales past 3/5Y
4.51% 8.91%
EPS Y/Y TTM
-37.48%
Sales Y/Y TTM
0.44%
EPS Q/Q
2.63%
Sales Q/Q
5.60%
Insider Own
1.88%
Insider Trans
0.00%
Inst Own
110.04%
Inst Trans
3.46%
ROA
3.99%
ROE
11.20%
ROIC
4.80%
Gross Margin
55.91%
Oper. Margin
18.37%
Profit Margin
7.12%
SMA20
4.54%
SMA50
9.65%
SMA200
52.58%
Trades
Shs Outstand
45.47M
Shs Float
44.64M
52W High
123.77 -4.25%
52W Low
48.98 141.96%
Volatility
2.56% 2.86%
ATR (14)
3.51
RSI (14)
63.73
Beta
0.64
Rel Volume
1.06
Avg Volume
733.67K
Volume
777,438
Perf Week
0.19%
Perf Month
11.80%
Perf Quarter
48.30%
Perf Half Y
97.75%
Perf YTD
47.86%
Perf Year
130.79%
Perf 3Y
33.61%
Perf 5Y
65.17%
Perf 10Y
246.32%
Prev Close
116.16
Price
118.51
Change %
2.02%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KROLL MARK WDirectorNov 10 '25Buy70.561,40098,78424,757Nov 12 04:18 PM
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
CEOMr. Christopher A. Simon
CFOMr. James C. D'Arecca CPA
Executive VP & COOMr. Frank W. Chan Ph.D.
J.D.Ms. Michelle L. Basil Esq.
Executive VP & Chief Commercial OfficerMr. Roy Galvin